FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response	: 0.5							

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
$\cup$	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					0. 000		0(11) 0	n tine i	iii Cottiici		ilpaily Act C	71 10-10							
Name and Address of Reporting Person*     Henderson Molly				2. Issuer Name <b>and</b> Ticker or Trading Symbol Phathom Pharmaceuticals, Inc. [ PHAT ]									ck all app Direc	tionship of Report all applicable) Director		10% O	Owner		
(Last)	`	rst) (I	Middle)	, INC.	3. Date of Earliest Transaction (Month/Day/Year) 07/14/2023								<b>)</b>		Officer (give title below)  CFO a		Other (abelow)	specify	
100 CAMPUS DRIVE, SUITE 102				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	AM N.	J 0	7932											)		i filed by On i filed by Mo on		J	
(City)	(S	tate) (2	Zip)		Rule 10b5-1(c) Transaction Indication														
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - No	n-Derivat	tive S	ecur	ities	Acq	uired,	Dis	posed of	, or	Ben	eficia	lly Owr	ned			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day				Execution Date,			Oate,	Transaction Disposed Of Code (Instr. 5)			ies Acquired (A) ο Of (D) (Instr. 3, 4 ε			Securi Benefi Owned Follow	cially I ing	Form (D) o	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A (D	A) or D)	Price		rted action(s) . 3 and 4)				
Common Stock 07/14/20					.023			A		25,000 <sup>(1</sup>	l)	Α	\$1	95	95,180 <sup>(2)</sup>		D		
Common Stock														1,1	1,134.27 <sup>(3)</sup>			By 401(K)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date Execu			Transaction Code (Instr.		ber vative vrities vired r osed r r, 3, 4	6. Date Exerc Expiration Da (Month/Day/Y		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		14)	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)			Expiration Date	Title	Amo or Num of Sha	ber					

## Explanation of Responses:

- 1. Represents restricted stock units ("RSUs") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- 2. Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023.
- 3. Includes 795.41 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.

## Remarks:

/s/ Larry Miller, Attorney-in-Fact for Molly Henderson

07/17/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.